Key Highlights

  • Second-quarter 2026 net sales were $898 million, down 4.1% from a year earlier, while adjusted EPS of $0.52 held roughly flat year over year.
  • The company generated $99 million in Operating Cash Flow and $55 million in free cash flow, ending June with $239 million in cash.
  • Management reiterated full-year 2026 guidance of $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50.

DENTSPLY SIRONA (NASDAQ: XRAY)'s shares have drifted lower again, keeping the dental-equipment maker firmly on the radar of value-focused investors watching for a turnaround. Trading near $10.72 and down about 2.5% on the session, XRAY sits well below where it stood a few years ago, a reflection of soft demand, restructuring and a multi-year effort to stabilize the business. The company's most recent Quarterly Report showed a mix of pressure and resilience, giving the market plenty to weigh as management pushes its self-styled Return-to-Growth Action Plan.

Company and Latest Development

DENTSPLY SIRONA Inc. (NASDAQ: XRAY) is one of the world's largest manufacturers of professional dental products and technologies, spanning imaging systems, CAD/CAM equipment, orthodontic clear aligners, implants, endodontic tools and consumables. On August 6, 2026, the company reported second-quarter 2026 results that captured its balancing act: net sales of $898 million slipped 4.1% from a year earlier, and fell 6.3% on a constant-currency basis, underscoring the Demand and competitive headwinds still facing the dental market. Yet profitability held firmer than the top line, with adjusted Earnings Per Share of $0.52 essentially flat year over year and adjusted EBITDA of $190 million at a 21.3% margin. GAAP diluted EPS came in at $0.18.

What Is Driving Attention Around XRAY?

The modest pullback in the shares does not trace to a single confirmed, same-session catalyst. Dentsply Sirona's most recent scheduled news was the August quarterly report, and in early September the company said it would present at the Baird 2026 Global Healthcare Conference. Small daily moves in a large-cap stock like this frequently reflect broader sector sentiment, currency shifts and portfolio positioning rather than fresh company-specific news. Investors tracking XRAY are more likely responding to the longer arc of the turnaround story than to any verified one-day event.

Key Numbers and Company Position

Beyond the headline sales decline, the second quarter showed disciplined cash management. Dentsply Sirona generated $99 million in operating cash flow and $55 million in free cash flow, ended June with $239 million in cash, and repurchased about 1.3 million shares for roughly $12 million. Management reiterated full-year 2026 guidance of $3.5 billion to $3.6 billion in net sales and adjusted EPS of $1.40 to $1.50. The stock carries a market Capitalization near $2.1 billion.

What Could Come Next?

The next scheduled catalyst is likely third-quarter 2026 results, expected in the autumn, which will test whether Chief Executive Dan Scavilla's Return-to-Growth Action Plan is gaining traction across distributor partnerships and a realigned sales force. Progress on new product launches in imaging and clear aligners, Margin trends, and any change to full-year guidance could shape sentiment. Commentary from the Baird healthcare conference and any further capital-return moves are also worth monitoring in the weeks ahead.

Risks to Watch

Dentsply Sirona still faces meaningful risks. Revenue has been contracting, and a further deterioration in dental-equipment demand or intensifying clear-aligner competition could pressure results. Currency swings weigh on a globally diversified sales base, and the company continues to work through restructuring after prior years of write-downs and management turnover. Execution risk on the turnaround plan remains the central concern, and the reaffirmed guidance depends on stabilizing the top line.

Conclusion

Dentsply Sirona enters the back half of 2026 as a turnaround-in-progress: sales are still declining, but margins, cash flow and reaffirmed guidance suggest a Business working to steady itself. With the shares near $10.72 and trading below the average analyst target, investors may be watching third-quarter results, the pace of the Return-to-Growth plan and any shift in guidance as the key developments that could influence sentiment around XRAY in the months ahead.